Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM versus CEPTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM versus CEPTAZ.
CEFUROXIME SODIUM vs CEPTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime sodium is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and causing cell lysis.
750 mg to 1.5 g IV or IM every 8 hours; maximum 6 g per day.
1 to 2 g intravenously every 8 to 12 hours; maximum 6 g per day.
None Documented
None Documented
Terminal elimination half-life: 1.2 hours (range 1-2 hours) in patients with normal renal function; prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min); dosing adjustment required for CrCl <30 mL/min
Approximately 2 hours in patients with normal renal function; prolonged to 3-5 hours in mild-moderate renal impairment and >20 hours in severe renal impairment (CrCl <10 mL/min).
Renal (95% unchanged via glomerular filtration and tubular secretion); biliary/fecal (minimal, <5%)
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <10%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic